Waldencast Sells Obagi Medical – Now All-In on Milk Makeup Growth
Waldencast sells Obagi Medical to Bridgepoint for up to $460M, pays debt, and focuses fully on Milk Makeup growth.
/ 352 items
#XY Event-Driven Stocks↓
No More Shots for Kids! FDA Approves Inhaled Afrezza 6+
The FDA has just approved MannKind’s Afrezza—the first inhaled insulin for children aged 6 and older with Type 1 and Type 2 diabetes.
Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus
Oculis eye drops failed main vision goal in DME trials but reduced swelling; no FDA filing, company shifts focus, strong cash until 2029.
C4 Therapeutics Shares Rocket as Bristol Myers Squibb’s Mezigdomide Phase 3 Triumph Lights Up Protein Degrader Sector
C4 Therapeutics stock jumped after Bristol Myers Squibb announced strong Phase 3 SUCCESSOR-2 results for mezigdomide in multiple myeloma.
Replimune Stock Explodes as FDA Gives Skin Cancer Drug RP1 a Third Chance!
Replimune stock jumped after FDA gave RP1 melanoma drug another approval chance with fast review and resubmission.
Tempus AI Gets FDA Green Light for Simpler Tumor-Only Cancer Test
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.